Trial Profile
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Urelumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacodynamics; Therapeutic Use
- 19 Apr 2023 Results(n=15) assessing Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas presented at the 114th Annual Meeting of the American Association for Cancer Research
- 03 Apr 2023 Planned End Date changed from 30 Jun 2024 to 31 Dec 2025.
- 03 Apr 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2024.